Literature DB >> 6852202

Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.

A M Landolt, H Minder, V Osterwalder, T A Landolt.   

Abstract

The morphometric analysis of the size of adenomatous prolactin cells shows that bromocriptine-induced cell shrinkage halts if treatment with the drug is discontinued for more than 2 days. Different cell components (nucleus, cytoplasm, nucleolus) do not react to treatment to the same extent.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6852202     DOI： 10.1007/bf01971131

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  7 in total

1.  Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP.

Authors:  R A Maurer
Journal:  Nature       Date:  1981-11-05       Impact factor: 49.962

2.  Structural changes in human pituitary tumor after bromocriptine therapy.

Authors:  S S Rengachary; T Tomita; B F Jefferies; I Watanabe
Journal:  Neurosurgery       Date:  1982-02       Impact factor: 4.654

3.  Direct antiproliferative effect of dopamine agonists on the anterior pituitary gland in organ culture.

Authors:  M Pawlikowski; J Kunert-Radek; H Stepień
Journal:  J Endocrinol       Date:  1978-11       Impact factor: 4.286

4.  Cerebrospinal fluid rhinorrhea: a complication of therapy for invasive prolactinomas.

Authors:  A M Landolt
Journal:  Neurosurgery       Date:  1982-09       Impact factor: 4.654

5.  Ergot-induced inhibition of pituitary tumor growth in rats.

Authors:  S K Quadri; K H Lu; J Meites
Journal:  Science       Date:  1972-04-28       Impact factor: 47.728

6.  Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells.

Authors:  R A Maurer
Journal:  J Biol Chem       Date:  1980-09-10       Impact factor: 5.157

7.  Practical stereological methods for morphometric cytology.

Authors:  E R Weibel; G S Kistler; W F Scherle
Journal:  J Cell Biol       Date:  1966-07       Impact factor: 10.539
  7 in total
  8 in total

1.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

2.  Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery.

Authors:  Yingxiao Cao; Fengju Wang; Zhenbo Liu; Baohua Jiao
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

3.  Pituitary adenomas in patients under 20 years old. A clinicopathological study of 12 cases.

Authors:  K Mukai; E L Seljeskog; L P Dehner
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

4.  Topical effect of bromocriptine on rat-transplanted human prolactinomas.

Authors:  B Açikgöz; T Ozgen; O E Ozcan; S Ruacan; T Erbengi; M Sumnu
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

5.  Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats.

Authors:  D J McComb; P Hellmann; M O Thorner; D Scott; W S Evans; K Kovacs
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

6.  Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cells.

Authors:  A M Landolt; V Osterwalder; T A Landolt
Journal:  Experientia       Date:  1985-05-15

7.  Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).

Authors:  Alireza M Manuchehri; Thozhukat Sathyapalan; Martin Lowry; Lindsay W Turnbull; Christopher Rowland-Hill; Stephen L Atkin
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 8.  Diagnosis and drug therapy of prolactinoma.

Authors:  E Ciccarelli; F Camanni
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.